Obesity and liver disease: the epidemic of the twenty-first century.
暂无分享,去创建一个
[1] J. Rosenstock,et al. Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes , 2012, Diabetes Care.
[2] S. Nair,et al. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. , 2010, The Journal of clinical endocrinology and metabolism.
[3] R. Groszmann,et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis , 2011, Hepatology.
[4] S. Klein,et al. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. , 2013, The Journal of clinical endocrinology and metabolism.
[5] E. Esrailian,et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. , 2004, Journal of hepatology.
[6] C. Bouchard,et al. Bariatric surgery and long-term cardiovascular events. , 2012, JAMA.
[7] S. Gortmaker,et al. Health and economic burden of the projected obesity trends in the USA and the UK , 2011, The Lancet.
[8] K. Gadde,et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.
[9] Joel Z Stengel,et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.
[10] P Boffetta,et al. Metabolic syndrome and hepatocellular carcinoma risk , 2012, British Journal of Cancer.
[11] J. Auwerx,et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation , 2006, Nature.
[12] E. Brunt,et al. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. , 2012, Journal of hepatology.
[13] Jimmy D Bell,et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study , 2004, Gut.
[14] J. Dixon,et al. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.
[15] F. Greenway,et al. Blood Pressure and Heart Rate Effects, Weight Loss and Maintenance During Long‐Term Phentermine Pharmacotherapy for Obesity , 2011, Obesity.
[16] Jonathan C. Cohen,et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.
[17] P. Misery,et al. Portal sensing of intestinal gluconeogenesis is a mechanistic link in the diminution of food intake induced by diet protein. , 2005, Cell metabolism.
[18] N. Weissman,et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. , 2011, The Journal of clinical endocrinology and metabolism.
[19] N. Rasgon,et al. Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients. , 2011, Journal of psychiatric research.
[20] Michael J Thun,et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.
[21] J. Marrero,et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. , 2005, Journal of hepatology.
[22] R. Leibel,et al. Changes in energy expenditure resulting from altered body weight. , 1995, The New England journal of medicine.
[23] A. Lok,et al. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. , 2009, Gastroenterology.
[24] S. Woods,et al. Central nervous system control of food intake , 2000, Nature.
[25] G. Loss,et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? , 2002, Hepatology.
[26] G. Farrell,et al. Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.
[27] R. Newbold. Impact of environmental endocrine disrupting chemicals on the development of obesity , 2010, Hormones.
[28] M. W. Schwartz,et al. Central nervous system control of food intake and body weight , 2006, Nature.
[29] Michael Charlton,et al. Cirrhosis and liver failure in nonalcoholic fatty liver disease: Molehill or mountain? , 2008, Hepatology.
[30] A. Astrup,et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.
[31] T. Schwartz,et al. Psychiatric medication‐induced obesity: a review , 2004, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[32] D. Nitka,et al. The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis , 2010, International Journal of Obesity.
[33] H. Yoo,et al. Prevalence of Transaminase Abnormalities in Asymptomatic, Healthy Subjects Participating in an Executive Health-Screening Program , 2003, Digestive Diseases and Sciences.
[34] S. Heymsfield,et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. , 1999, JAMA.
[35] J. Proietto,et al. The defence of body weight: a physiological basis for weight regain after weight loss. , 2013, Clinical science.
[36] N. Weissman,et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. , 2010, The New England journal of medicine.
[37] R. Sturm. Increases in clinically severe obesity in the United States, 1986-2000. , 2003, Archives of internal medicine.
[38] B. Swinburn,et al. An “ecological” approach to the obesity pandemic , 1997, BMJ.
[39] K. Flegal,et al. Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories , 2012 .
[40] F. Foufelle,et al. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1c , 2010, Diabetes, obesity & metabolism.
[41] Claude Bouchard,et al. Effects of bariatric surgery on mortality in Swedish obese subjects. , 2007, The New England journal of medicine.
[42] Deepak L. Bhatt,et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. , 2012, The New England journal of medicine.
[43] Katsutoshi Tokushige,et al. Clinical features and outcomes of cirrhosis due to non‐alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C , 2009, Journal of gastroenterology and hepatology.
[44] D. Matthews,et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.
[45] Benjamin Caballero,et al. Will All Americans Become Overweight or Obese? Estimating the Progression and Cost of the US Obesity Epidemic , 2008, Obesity.
[46] K. Gadde,et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study , 2011, The American journal of clinical nutrition.
[47] G. Bray,et al. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. , 2012, Archives of internal medicine.
[48] A. Baranova,et al. Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.
[49] V. Beral,et al. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study , 2010, BMJ : British Medical Journal.
[50] Katherine M Flegal,et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. , 2012, JAMA.
[51] Ralph B D'Agostino,et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. , 2002, Archives of internal medicine.
[52] S. Kini,et al. Nutritional Deficiencies following Bariatric Surgery: What Have We Learned? , 2005, Obesity surgery.
[53] J. Vallé-Jones,et al. A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice. , 1983, Pharmatherapeutica.
[54] S. Inzucchi. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. , 2002, JAMA.
[55] B. Leroux,et al. Identification of Body Fat Mass as a Major Determinant of Metabolic Rate in Mice , 2010, Diabetes.
[56] David M Nathan,et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.
[57] Daniel B. Jones,et al. First Report from the American College of Surgeons Bariatric Surgery Center Network: Laparoscopic Sleeve Gastrectomy has Morbidity and Effectiveness Positioned Between the Band and the Bypass , 2011, Annals of surgery.
[58] Theo Stijnen,et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. , 2010, Archives of general psychiatry.
[59] P. Bedossa,et al. Risk factors of fibrosis in alcohol‐induced liver disease , 2002, Hepatology.
[60] E. Mardis,et al. An obesity-associated gut microbiome with increased capacity for energy harvest , 2006, Nature.
[61] W. Langhans. Role of the liver in the control of glucose‐lipid utilization and body weight , 2003, Current opinion in clinical nutrition and metabolic care.
[62] N. Stylopoulos,et al. Roux‐en‐Y Gastric Bypass Enhances Energy Expenditure and Extends Lifespan in Diet‐induced Obese Rats , 2009, Obesity.
[63] W. Langhans,et al. Intrameal hepatic-portal infusion of glucose reduces spontaneous meal size in rats , 2001, Physiology & Behavior.
[64] M. Christensen,et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials , 2012, BMJ : British Medical Journal.
[65] William W Eaton,et al. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. , 2003, American journal of epidemiology.
[66] Margaret Anderson,et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. , 2008, JAMA.
[67] Lee M. Kaplan,et al. Conserved Shifts in the Gut Microbiota Due to Gastric Bypass Reduce Host Weight and Adiposity , 2013, Science Translational Medicine.
[68] C. Weyer,et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. , 2004, Obesity research.
[69] F. Greenway,et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2010, The Lancet.
[70] J. Wang,et al. Body fat topography as an independent predictor of fatty liver. , 1993, Metabolism: clinical and experimental.
[71] Hyon K. Choi,et al. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. , 2007, Archives of internal medicine.
[72] E. Negri,et al. Diabetes Mellitus and Cancer Risk in a Network of Case-Control Studies , 2012, Nutrition and cancer.
[73] P. Even,et al. Body weight, body composition, and energy metabolism in lean and obese Zucker rats fed soybean oil or butter. , 2002, The American journal of clinical nutrition.
[74] K. Batts,et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.
[75] Gretchen A. Stevens,et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants , 2011, The Lancet.
[76] D. Drucker,et al. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks , 2010, Diabetes Care.
[77] M. Crowell,et al. Human gut microbiota in obesity and after gastric bypass , 2009, Proceedings of the National Academy of Sciences.
[78] Rocio Lopez,et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.
[79] R. Collins,et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, Lancet.
[80] Y. Iwamoto,et al. Prevalence of non‐alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[81] N. Newman,et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). , 2007, American journal of ophthalmology.
[82] C. Beglinger,et al. Bile acids and gut peptide secretion after bariatric surgery: A 1‐year prospective randomized pilot trial , 2013, Obesity.
[83] N. Nguyen,et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. , 2008, Journal of the American College of Surgeons.
[84] Heinrich Taegtmeyer,et al. Obesity and the risk of heart failure. , 2002, The New England journal of medicine.